Eli Lilly And Co & Ors v Genetech Inc

Eli Lilly And Co & Ors v Genetech Inc

Permission is refused because Lilly failed to comply with mandatory procedural requirements for admission of experimental evidence, causing prejudice to Genetech and disregarding court orders and established practice.

Parties
Claimant: Eli Lilly and Company; Claimant: Lilly France SAS; Claimant: Lilly Deutschland GmbH; Claimant: Eli Lilly Italia SPA; Claimant: Eli Lilly and Co (Ireland) Limited; Claimant: Eli Lilly Kinsale Limited; Claimant: Lilly SA; Claimant: Eli Lilly and Company Limited; Defendant: Genetech, Inc
Jurisdiction
England and Wales
Judgment Date
13 December 2018
Procedural Posture
Patent / Pre Trial Review
Outcome
permission refused
Legal Topics
Admissibility of Experimental Evidence, Procedural Compliance, Litigation Practice
Intellectual Property Patents Admissibility of Experimental Evidence Procedural Compliance Litigation Practice

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 1 Party arguments 2
Sign in to unlock

Parties

Eli Lilly and Company

Claimant

Lilly France SAS

Claimant

Lilly Deutschland GmbH

Claimant

Eli Lilly Italia SPA

Claimant

Eli Lilly and Co (Ireland) Limited

Claimant

Eli Lilly Kinsale Limited

Claimant

Lilly SA

Claimant

Eli Lilly and Company Limited

Claimant

Genetech, Inc

Defendant

Procedural Posture

Patent / Pre Trial Review

Legal Issues

  1. 1 Whether Lilly should be granted permission to rely on Novartis experiments conducted for EPO proceedings without complying with court procedure

Ratio Decidendi

Permission is refused because Lilly failed to comply with mandatory procedural requirements for admission of experimental evidence, causing prejudice to Genetech and disregarding court orders and established practice.

Court Disposition

permission refused

Orders

  • Lilly is refused permission to rely on the Novartis experiments in these proceedings.